Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

S&P 500 EPS growth is expected to come in at 4.8% for Q2, which would be the lowest growth rate since Q4 2023.

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Q1 2025 earnings presentation From Dupixent, Q1 2025 saw $1.53 billion in revenue, as the drug achieved global net sales, split with Sanofi, of $3.7 billion.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Next earnings report is scheduled for 31 days from now. Professional Analyst Ratings for Regeneron Pharmaceuticals 5 market experts have recently issued ratings for this stock, with a consensus ...